**Background**
Prostate cancer remains one of the most prevalent malignancies in men, often progressing to invasive and metastatic stages that are difficult to treat. A key area of research in combating this disease involves the study of epigenetic modifications, specifically the role of epigenetic reader domains that recognize acetylated lysine residues on histone tails. BAZ2A (Bromodomain Adjacent to Zinc Finger Domain 2A) is a critical protein containing a bromodomain that plays a significant role in chromatin remodeling and gene expression regulation. Dysregulation of BAZ2A has been implicated in the progression of various cancers, making it an attractive target for therapeutic intervention. In the context of 4-Chloro-N-methylpicolinamide Epigenetic Reader Domain research, targeting BAZ2A may provide new insights into inhibiting the growth and invasion of prostate cancer cells. Therefore, we will introduce a BAZ2A bromodomain inhibitor – 4-Chloro-N-methylpicolinamide.
**Definition**
4-Chloro-N-methylpicolinamide is a small molecule BAZ2A bromodomain inhibitor with a dissociation constant (Kd) of >500 μM.
**Mechanism of Action**
According to the 4-Chloro-N-methylpicolinamide description, this compound functions by interacting with the BAZ2A bromodomain. Specifically, 4-Chloro-N-methylpicolinamide forms a weak hydrogen bond with the carbonyl oxygen of the Pro1817 residue within the target protein. This interaction allows researchers to probe the binding pocket of BAZ2A and evaluate the effects of bromodomain inhibition on cellular processes. For researchers seeking detailed 4-Chloro-N-methylpicolinamide technical information, this compound serves as a valuable tool for studying the structural biology of BAZ2A and its role in the epigenetic landscape of invasive prostate cancer.
**In Vitro Studies**
The 4-Chloro-N-methylpicolinamide biological activity has been characterized through binding assays to determine its affinity for the BAZ2A bromodomain. In vitro studies demonstrated that the compound exhibits a Kd value of >500 μM, indicating a relatively weak binding affinity. Despite this, the compound provides a necessary chemical scaffold for the discovery and optimization of more potent BAZ2A ligands. These studies highlight the potential of targeting BAZ2A to modulate the expression of genes involved in cancer cell invasion. In conclusion, 4-Chloro-N-methylpicolinamide is a BAZ2A bromodomain inhibitor useful for the research of invasive prostate cancer.
Keywords
4-Chloro-N-methylpicolinamide, 220000-87-3, Epigenetic Reader Domain, invasive prostate cancer, Inhibitor, inhibitor, inhibit
References